Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
... for the acute and maintenance treatment of schizophrenia
in adults on Friday, July 31, 2009. It is the ... percent of the world's population suffers from schizophrenia
- a brain disorder that impairs a person's ...
Unfortunately, 80 percent of patients with schizophrenia
experience at least one relapse within five years ...
FDA Advisory Committee Votes in Favor of SAPHRIS(R) (asenapine) for Acute Bipolar I Disorder and Acute Schizophrenia
... adults and in favor of use in acute treatment of schizophrenia
in adults. If approved by FDA, SAPHRIS would be ... a significant unmet need for patients with schizophrenia
and bipolar I disorder, including patients ... and 10/0/2) for the bipolar I disorder and schizophrenia
indications, respectively. In addition, the ...
deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia
... -- The largest study of
the genetics of schizophrenia
ever undertaken has revealed several new ... suggesting a possible
environmental link between schizophrenia
immune response. It has long been
known, for ... and controls from the International schizophrenia
and the European-American ...
ADHD Genes Found; Known to Play Roles in Neurodevelopment
... roles in many diseases, including autism and schizophrenia
Everyone has CNVs in their DNA, but not all of ... neurodevelopmental disorders, including autism, schizophrenia
and Tourette syndrome. The CNVs found in ADHD ... the CNVs found in ADHD that also occur in autism, schizophrenia
and other neurological disorders. This overlap ...
FDA Advisory Committee Votes in Favor of Zyprexa for Two Adolescent Indications
... and acceptably safe for the acute treatment of schizophrenia
or manic or mixed episodes associated with ... by their recommendations.
For the proposed schizophrenia
indication, the panel voted 11-5, with two ... clinical trials of Zyprexa in adolescents with schizophrenia
or bipolar I disorder, including a six-week ...
Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry
... for lurasidone in the treatment of patients with schizophrenia
have been published in The Journal of Clinical ... hospitalized for an acute exacerbation of schizophrenia
(diagnosed using DSM-IV criteria). A total of ... H(1) or acetylcholine M(1) receptors.
Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
... or CGI-S at study endpoint.
"People with schizophrenia
need new treatment options that offer a ... psychiatry and neuroscience and director of the schizophrenia
research program at the University of Cincinnati ... acute schizophrenia. Patients were diagnosed with schizophrenia
(using DSM-IV criteria) and were required to have ...
RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder
... antipsychotic therapy used for the treatment of schizophrenia
and the maintenance treatment of Bipolar I ... the most common side effects in the treatment of schizophrenia
were headache, tremors, dizziness, restlessness, ... reactions in clinical trials in patients with schizophrenia
(greater than or equal to 5%) were headache, ...
FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia
The efficacy of Fanapt(TM) for the treatment of schizophrenia
was supported by two placebo-controlled ... be superior to placebo in controlling symptoms of schizophrenia
across doses of 12mg to 24mg per day. The ... other antipsychotics are tried first.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
... treatment options for patients diagnosed with schizophrenia
or schizoaffective disorder.
Earlier this ... disorder is sometimes misdiagnosed as schizophrenia
or bipolar disorder. For patients who frequently use mental health services, schizophrenia
and schizoaffective disorder may account for ...
Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
... compound optimization criteria. Omeros' schizophrenia
product candidates inhibit the phosphodiesterase ... strength of the preclinical data generated by our schizophrenia
program," said Gregory A. Demopulos, M.D., ... of the agreement with SMRI.
FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults
... (LAI) for acute and maintenance treatment of schizophrenia
adults. Lilly is continuing to work with the ... for an extended period of time.(3)
is a severe and debilitating illness with such ...
Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
acute treatment of agitation in patients with schizophrenia
disorder. AZ-004 is being developed ... from major psychiatric
disorders, including schizophrenia
and bipolar disorder. Patients
experiencing ... the company believes that in the United
afflicts about 2.5 million adults and bipolar ...
AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia
... by AstraZeneca in cognitive dysfunction in schizophrenia
(CDS), known as the HALO trial.
About Cognitive Dysfunction in schizophrenia
is a chronic, severe and disabling form of ...
Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia
... agonist, in cognitive impairment associated with schizophrenia
(CIAS). The Company has randomized 212 patients ... a nicotinic alpha-7 receptor agonist in schizophrenia
and we are pleased to have reached this important ... to include approximately 212 patients with stable schizophrenia
who are receiving atypical antipsychotic therapy. ...
Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder
... condition, which encompasses the symptoms
of both schizophrenia
and a major mood disorder. Patients ... disorder can be difficult to
distinguish from schizophrenia
or bipolar disorder because the symptoms ... that frequently use mental health
and schizoaffective disorder may account ...
Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program
... 3454 in cognitive impairment
associated with schizophrenia
(CIAS). Memory Pharmaceuticals is ... The Phase 2 trial is in patients with stable schizophrenia
receiving atypical antipsychotic therapy. ... objectives include measures
of other symptoms of schizophrenia
and functional capacity.
About R3487/MEM 3454
Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months
... have been
associated with improved treatment of schizophrenia
in patients who have
difficulty adhering to daily ... LAI may play in
the treatment of patients with schizophrenia
who have benefited from
olanzapine but continue ... study, a total of 1,065 adult
outpatients with schizophrenia
who had been stabilized previously with
deCODE and SGENE Consortium Discover Deletions in the Human Genome Linked to Risk of Schizophrenia
... individuals with certain mental
disorders such as schizophrenia
tend to have few children, and thus that we
may ... then tested these variants for association
in more than 1,400 schizophrenics and 33,000 ... 15q11 and 15q13 were
suggestively associated with schizophrenia
in this first phase, and then
validated in 3,300 ...
Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
... study (HGKB) were presented at the
first annual schizophrenia
International Research Society (SIRS) ... LAI as a
maintenance treatment for patients with schizophrenia
who may have
difficulty taking medication on a ... study, a total of 1,065 adult
outpatients with schizophrenia
who had been stabilized previously on
Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
... treatment of acute agitation in patients with schizophrenia
disorder. Alexza believes the novel, ... many major psychiatric disorders, including schizophrenia
disorder. According to the National ... suggests that many patients with schizophrenia
disorder are able to make informed ...
NARSAD Researchers Identify Specific Genes and Family Traits Linked to Schizophrenia, Bipolar Disorder and Depression
Donald C. Goff, MD, director of the schizophrenia
Clinical and Research
Program at Massachusetts ... Benefit?
Do genes explain why some people with schizophrenia
are helped when
they take supplements of the ... low blood levels of folate and negative schizophrenia
folate is involved in many different ...
Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting
... of asenapine in the treatment of schizophrenia
and bipolar I disorder
WASHINGTON, May 8 ... from a clinical trial
involving patients with schizophrenia
and schizoaffective disorders.
Asenapine, a ... extension and in two out
of four short-term schizophrenia
studies. In the third short-term
Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events
effective in the short-term treatment of schizophrenia
and that iloperidone
is non-inferior to ... blood
glucose, body weight and lipid profiles.
is a chronic, severe and disabling disorder that ... remains among patients with schizophrenia
physicians who treat them. The recent ...
Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
... -- Nearly half of patients
fail to remain on their medication treatment, ... longer-term
maintenance therapy of patients with schizophrenia
or other related
disorders (schizoaffective ... RLAI offers a significant
benefit to people with schizophrenia
in delaying the time to relapse," said
EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
... of its
alpha-7 nicotinic agonist (EVP-6124) in schizophrenia
treated with atypical ... This trial is enrolling approximately 20 schizophrenia
with a stable dose of an ... About Electrophysiological Biomarkers in schizophrenia
Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
... measure that is abnormal in patients
is mismatched negativity, which is the ability to ... Both of these evoked
potential abnormalities in schizophrenia
have been shown to be reversed by
disorders such as Alzheimer's disease, schizophrenia
and depression. For
additional information, ...
Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
... last week at the 14th Biennial
Winter Workshop on schizophrenia
and Bipolar Disorders. ITI-007 is
currently in ... ITI-002 to treat cognitive dysfunction in schizophrenia
remains an important quality of life issue ... with Parkinson's disease.
is a major neuropsychiatric disorder that affects ...
FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
... for the treatment and maintenance treatment
in adults, Eli Lilly and Company (NYSE: LLY ) ... period of time(iii).
is a severe and debilitating illness often ... In addition to these symptoms, patients
are at greater risk for medical comorbidities ...
Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
... is developing ITI-007 for the
treatment of schizophrenia
and other related psychiatric conditions.
In ... a personalized approach to patient treatment
providing an ability to 'dial-in' the optimal D2 ... significant weight gain.
is a major neuropsychiatric disorder that affects ...
New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia
"Patients with schizophrenia
and their physicians need to have a
variety of ... overview
In the study, 448 adult patients with schizophrenia
asenapine 5 mg twice daily, ... 10 percent for placebo.
is a chronic, disabling brain disorder ...
Vanda Presents Phase III Iloperidone Efficacy Data
... greater improvements in the
symptoms of schizophrenia
versus placebo and has a favorable safety ... that should
be very good news for patients with schizophrenia
and the physician
community," said Dr. Peter ... parallel-group, six-week trial of patients
or schizoaffective disorder. The analysis ...
Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
... approval from the FDA for the treatment
and acute mania or mixed episodes associated with ... clinical trial program thus far has consisted of schizophrenia
bipolar mania trials involving nearly 3,000 ... two years later(5).
is a chronic, disabling brain disorder ...
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
... for maintenance treatment of schizophrenia
in adult patients. On
May 17, 2007, the FDA ... treatment of
schizophrenia in adult patients. schizophrenia
patients experience high rates of symptom ... these patients
are treated with SEROQUEL XR." schizophrenia
is a serious brain disorder with symptoms ...
EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimer's, Schizophrenia and Huntington's Diseases
... several key
programs for addressing Alzheimer's, schizophrenia
diseases. EnVivo ... U.S. Food and Drug
Administration for a Phase IIA schizophrenia
study that is scheduled to
begin in early 2008. ... compounds will
improve cognitive function in schizophrenia
and Alzheimer's patients. Additionally, the ...
Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
... study of RGH-188, a novel
antipsychotic, in 389 schizophrenia
patients. The protocol-specified
primary endpoint ... effect compared to placebo in the treatment of schizophrenia
the low dose arm and a numerical improvement ... the development of
RGH-188 as a treatment for schizophrenia
and will determine the appropriate
INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
... -- Acutely ill, hospitalized
patients with schizophrenia
showed significant improvement in symptoms
after ... tremor (20%, 8%,
15%), dizziness (4%, 15%, 1%), schizophrenia
(6%, 9%, 13%) and insomnia
(12%, 10%, 15%). ... reported in more than two
percent of patients was schizophrenia
(INVEGA 4%, SEROQUEL 2%, and placebo
Vanda Pharmaceuticals Submits Iloperidone New Drug Application
... instrument in the treatment
of patients with schizophrenia
and may help to usher the field of
psychiatry ... "The application of personalized medicine in schizophrenia
significant because response to drugs varies ... Alliance on Mental
Illness). Unmet Needs in schizophrenia
U.S. FDA Issues Complete Response Letter for SAPHRIS(TM) (ASENAPINE) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
... for SAPHRIS(TM) (asenapine) sublingual tablets in the acute treatment of schizophrenia
in adults and in the acute treatment of manic or mixed episodes associated ... data from a clinical trial program involving more than 3,000 patients in schizophrenia
and bipolar mania trials.
Schering-Plough is an innovation-driven, ...
Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
... were two serious adverse events reported during the trial:
exacerbation of schizophrenia
(1 patient in the placebo group) and
gastroenteritis (1 patient in the 10 ... common and severe symptoms
of many major psychiatric disorders, including schizophrenia
disorder. According to the National Institute of Mental Health ...